List of Excipients in Branded Drug CEFOXITIN AND DEXTROSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	CEFOXITIN AND DEXTROSE	cefoxitin sodium	0264-3123	DEXTROSE
B Braun Medical Inc	CEFOXITIN AND DEXTROSE	cefoxitin sodium	0264-3123	WATER

Cefoxitin and Dextrose Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 16, 2026

Cefoxitin and dextrose is a mature sterile-injectable combination with limited composition-of-matter patent risk and greater commercial differentiation potential in formulation, container technology, supply reliability, and hospital workflow. The strongest product opportunity is a ready-to-use cefoxitin sodium injection in 5% dextrose injection, supported by validated stability, low preparation burden, and reliable supply.

What is the regulatory status of cefoxitin and dextrose injection?

Cefoxitin is a second-generation cephamycin antibacterial supplied as cefoxitin sodium for intravenous or intramuscular administration. Dextrose injection, usually 5% dextrose in water, is used as the infusion vehicle rather than as an antimicrobial component.

Attribute	Cefoxitin and dextrose
Active pharmaceutical ingredient	Cefoxitin sodium
Common infusion vehicle	5% dextrose injection, USP
Dosage form	Sterile intravenous solution or powder requiring reconstitution
Therapeutic class	Cephamycin antibacterial
Primary users	Hospitals, surgical centers, emergency departments
Major clinical uses	Intra-abdominal, gynecologic, urinary-tract, skin and soft-tissue infections; surgical prophylaxis
Regulatory pathway	Generic injectable approval, generally under an ANDA or an approved NDA
Regulatory maturity	Long-established product with no meaningful remaining new-drug exclusivity
Commercial differentiation	Premix convenience, stability, packaging, supply, and hospital economics

The original cefoxitin product, Mefoxin, was approved in the United States in the late 1970s. Current products are primarily generic cefoxitin sodium presentations, including vials and premixed infusion products. FDA labeling identifies dextrose-containing solutions as acceptable diluents for cefoxitin, subject to concentration, storage, and administration conditions in the applicable label.[1,2]

What excipients are used in cefoxitin and dextrose products?

The central excipient is dextrose, typically supplied as 5% dextrose injection. The formulation may also contain pH-adjusting agents or processing-related components, depending on the manufacturer and presentation.

Dextrose

A 5% dextrose solution contains approximately 50 mg/mL of dextrose. In a 50 mL container, the vehicle contains approximately 2.5 g of dextrose. In a 100 mL container, it contains approximately 5 g.

Dextrose provides:

• A commercially established parenteral vehicle.
• Osmotic contribution that may improve infusion tolerability compared with highly concentrated drug solutions.
• A familiar hospital administration format.
• Compatibility with standard intravenous pumps and sets.
• A clear, low-particulate solution suitable for visual inspection.

Dextrose is not pharmacologically neutral for every patient. It may affect glucose management, fluid selection, and suitability for patients requiring sodium-containing fluids or restricted carbohydrate administration. Product labeling should identify the dextrose content and relevant clinical limitations.

pH control

Cefoxitin sodium is an alkaline salt. The final product must maintain a pH range that supports chemical stability, container compatibility, and patient tolerability. A manufacturer may use an acid or base for pH adjustment, but the selected system must be disclosed or controlled under the applicable regulatory filing.

The pH strategy is commercially relevant because cefoxitin can degrade through beta-lactam hydrolysis. Excessive exposure to heat, unfavorable pH, oxygen, or reactive container surfaces can reduce potency or increase degradation products.

Water for injection

Water for injection is the principal solvent in the dextrose vehicle. It must meet applicable compendial requirements for sterility, endotoxins, particulate matter, and chemical quality.

Container and closure materials

For a ready-to-use product, container selection is part of the excipient and stability strategy. Relevant options include:

• Flexible multilayer bags.
• Glass bottles.
• Polymer bottles.
• Dual-chamber or reconstitution systems.
• Small-volume plastic infusion containers.

The container must limit moisture loss, oxygen ingress, extractables, leachables, and adsorption. It must also tolerate terminal sterilization or validated aseptic processing, depending on the manufacturing approach.

What formulation strategy is strongest for cefoxitin and dextrose?

The most commercially defensible formulation is a ready-to-use intravenous premix with a validated refrigerated or controlled-room-temperature shelf life.

Strategy comparison

Formulation strategy	Advantages	Main limitations	Commercial assessment
Cefoxitin powder vial	Longest conventional shelf-life potential; flexible dosing	Requires pharmacy reconstitution; preparation errors; labor cost	Low differentiation
Cefoxitin vial plus separate D5W bag	Broad hospital familiarity; flexible volume	Requires multiple handling steps; greater preparation burden	Moderate utility
Ready-to-use cefoxitin in D5W	Lower preparation burden; fewer manipulations; easier nursing workflow	Stability and shipping requirements are more demanding	Highest differentiation
Extended-stability premix	Reduces waste and emergency preparation; supports decentralized care	Requires extensive stability data and packaging development	High value if validated
Concentrated ready-to-dilute solution	Lower shipping volume; flexible final dilution	More manipulation and potential dosing error	Selective opportunity
Dual-chamber container	Separates drug and vehicle until use; may improve stability	Higher device cost and regulatory complexity	Potential lifecycle product

A premix product should be designed around actual hospital use rather than nominal formulation simplicity. Critical development variables include drug concentration, infusion volume, administration time, storage temperature, light exposure, container orientation, agitation, and in-use stability.

What stability issues affect cefoxitin and dextrose?

Cefoxitin is a beta-lactam antibiotic and is vulnerable to hydrolytic degradation. A formulation program should evaluate:

1. Assay and degradation products.
2. pH drift.
3. Appearance and color.
4. Subvisible and visible particles.
5. Container closure integrity.
6. Sterility and bacterial endotoxins.
7. Compatibility with common infusion sets.
8. Stability after removal from controlled storage.
9. Stability after partial administration or simulated use.
10. Impact of temperature excursions during distribution.

Dextrose can support a commercially acceptable infusion vehicle, but the combination cannot be assumed to have the same shelf life as cefoxitin in a dry powder vial. Premixed products require product-specific stability evidence.

Published labeling for cefoxitin products commonly provides separate stability instructions for reconstituted solutions and diluted infusion solutions. Those instructions vary by concentration, diluent, container, and storage condition. A commercial product should rely on its own approved label rather than extrapolating from another manufacturer’s vial or dilution data.[1,2]

What patents protect cefoxitin and dextrose products?

The core cefoxitin molecule is no longer protected by enforceable U.S. composition-of-matter exclusivity. Cefoxitin was introduced decades ago, and the commercially relevant patent term for the original antibacterial compound has expired.

Patent estate assessment

Patent category	Current risk assessment
Cefoxitin composition patents	Expired
Cefoxitin sodium salt claims	Generally expired or commercially weak
Original antibacterial use claims	Expired or unlikely to block ordinary generic use
Dextrose injection composition	Established generic vehicle; no meaningful exclusivity
Standard vial formulations	Low patent differentiation
Premixed cefoxitin in D5W	Potentially protectable only through narrow formulation, container, process, or stability claims
Device and dual-chamber systems	Potentially protectable depending on ownership and claim scope
Manufacturing process	Potential protection if the process is novel and non-obvious
Hospital administration or dosing methods	Limited practical blocking power if routine use is already established

The potential patent value is therefore concentrated in secondary claims. These may cover:

• A defined cefoxitin concentration in 5% dextrose.
• A specified pH range.
• A particular polymer bag or closure.
• Oxygen-control or moisture-barrier packaging.
• A stability profile at a defined temperature.
• A dual-chamber activation sequence.
• A low-impurity manufacturing process.
• A specific infusion method or hospital-use configuration.

A formulation patent would need meaningful technical distinction. A claim that merely places an established cefoxitin sodium product into conventional D5W may face novelty, obviousness, and written-description challenges.

How many patents cover cefoxitin and dextrose?

No meaningful active U.S. patent barrier covers the basic cefoxitin-plus-dextrose concept. The practical number of blocking patents for a conventional generic premix is therefore close to zero, subject to product-specific freedom-to-operate review.

The relevant intellectual-property risk is not the old cefoxitin estate. It is the possibility that a competitor owns a narrow patent covering:

• A specific ready-to-use concentration.
• A particular flexible container.
• A long-term stability condition.
• A reconstitution or activation device.
• A manufacturing method that is difficult to design around.

FDA approval does not eliminate third-party patent risk. Conversely, the absence of a prominent Orange Book patent does not prove that no non-Orange-Book patent exists.

What is the Orange Book status of cefoxitin and dextrose?

The Orange Book is most relevant to approved drug products with listed patents and exclusivity. Cefoxitin and dextrose products are generally generic sterile injectables, and the basic combination does not have a meaningful period of remaining new-drug exclusivity.

For an ANDA applicant, the key regulatory questions are:

• Which product is the reference listed drug?
• Is the proposed presentation therapeutically equivalent to the reference product?
• Is the product a vial requiring reconstitution or a ready-to-use infusion?
• Does the formulation require a different regulatory pathway?
• Are any patents listed against the relevant reference product?
• Does the proposed product trigger Paragraph IV certification?

A Paragraph IV challenge has little commercial value when no unexpired, relevant Orange Book patent blocks the target product. It becomes important only if an innovator or generic sponsor has listed a formulation, use, or device patent that covers the proposed presentation.

When does cefoxitin lose exclusivity?

Cefoxitin lost practical market exclusivity years ago. The original product’s new-drug exclusivity and core patent rights are no longer relevant barriers to ordinary generic entry.

The current commercial protection period depends on the individual product, not the molecule. A newly approved cefoxitin and dextrose presentation could receive limited regulatory exclusivity only if it satisfies a statutory basis for such protection. A conventional generic premix would not normally receive meaningful new exclusivity simply because it uses D5W as the diluent.

Which companies are challenging cefoxitin patents?

The market is not defined by an active patent challenge cycle comparable to newer small-molecule medicines. Cefoxitin is a mature injectable generic category with competition based primarily on approved supply, manufacturing capacity, contracting, and shortage performance.

Potential competitors include:

• Generic sterile-injectable manufacturers.
• Branded-generic suppliers.
• Hospital-contract manufacturers.
• Outsourcing facilities supplying compounded or hospital-use products where legally permitted.
• Large injectable companies offering premixed antibiotic products.

No active, high-value Paragraph IV dispute is central to the ordinary cefoxitin and dextrose market based on the public regulatory profile of this mature product category.

What commercial opportunities exist for cefoxitin and dextrose?

The best opportunities arise from reducing hospital labor and supply risk.

Ready-to-use premix

A 50 mL or 100 mL ready-to-use container can eliminate pharmacy reconstitution and reduce manipulation at the point of care. The value proposition is strongest in:

• Surgical prophylaxis.
• Emergency departments.
• Operating rooms.
• Short-stay hospitals.
• Facilities with limited sterile-compounding capacity.
• Health systems seeking standardized antibiotic administration.

Extended shelf life

A product with a longer labeled shelf life can reduce product waste and improve inventory management. Shelf-life claims must be supported by real-time and accelerated stability studies in the marketed container.

Supply reliability

Cefoxitin is vulnerable to hospital purchasing decisions that prioritize availability over nominal unit price. A supplier with dual-source API procurement, validated alternate packaging, and reliable sterile-fill capacity may secure contracts even without patent protection.

Packaging differentiation

A flexible premix bag with clear labeling, barcode compatibility, tamper evidence, and infusion-set compatibility can create practical differentiation. These attributes are more likely to influence hospital purchasing than a narrow formulation patent.

Regional and international expansion

Outside the United States, opportunities may exist in markets where:

• Cefoxitin remains part of surgical prophylaxis protocols.
• Premixed antibiotics are underdeveloped.
• Hospital pharmacies have limited aseptic compounding capacity.
• Local procurement rewards ready-to-use presentations.
• Regulatory approval can rely on established active-ingredient data.

Geographic freedom-to-operate must be reviewed separately because expired U.S. rights do not establish the status of patents, regulatory data protections, or device rights in Europe, Japan, China, Canada, or emerging markets.

What generic launch risks exist?

A generic launch faces operational and regulatory risks rather than core molecule patent risk.

Risk	Impact
Cefoxitin degradation in D5W	Failed stability program or shortened shelf life
Particulate formation	Batch rejection, recall, or administration restriction
Container interaction	Loss of potency or extractables concern
Limited sterile manufacturing capacity	Supply interruption
Low hospital volume	Weak return on development investment
Price compression	Reduced margin after multiple entrants
Labeling mismatch	Restrictions on storage, dilution, or administration
Dextrose clinical limitations	Reduced use in selected patient populations
Alternative antibiotics	Loss of demand in hospitals with different protocols
API sourcing concentration	Exposure to shortages and quality events

How strong is the patent estate for cefoxitin and dextrose?

The patent estate is weak for the basic product and potentially moderate for a differentiated delivery system.

Patent dimension	Strength
Active ingredient	Very low
Dextrose vehicle	Very low
Conventional vial	Very low
Standard premix	Low
Specialized container	Moderate
Dual-chamber delivery	Moderate to potentially strong
Long-term stability platform	Moderate if technically distinctive
Manufacturing process	Variable
Brand protection	Low without meaningful formulation or device rights

A company should not base the investment case on patent exclusivity. The stronger case is operational: fewer preparation steps, reduced medication-handling risk, lower pharmacy labor, and dependable availability.

What licensing deals could support a cefoxitin and dextrose product?

Licensing is most relevant to technology rather than to the cefoxitin molecule. Potential deal targets include:

• Premix bag technology.
• Dual-chamber container systems.
• Low-oxygen packaging.
• Sterile-fill manufacturing capacity.
• Cefoxitin API supply.
• Hospital distribution contracts.
• Regional rights for registered injectable products.

A typical commercial structure would combine a technology license with contract manufacturing and territorial commercialization rights. Royalty economics are likely to be more attractive for a proprietary container or stability platform than for a conventional cefoxitin formulation.

Key Takeaways

• Cefoxitin and dextrose is a mature generic injectable combination with no meaningful core patent barrier.
• Dextrose 5% injection is the principal vehicle and supports a familiar hospital infusion format.
• The best product opportunity is a ready-to-use premix with strong stability, clear labeling, and reliable sterile supply.
• Formulation and container patents may protect a differentiated product, but a conventional cefoxitin-in-D5W presentation is unlikely to support broad exclusivity.
• Paragraph IV risk is limited unless a specific reference product has an unexpired listed formulation, use, or device patent.
• Commercial success depends on hospital workflow, shortage resilience, contract pricing, and container performance.
• The highest-value technical work concerns beta-lactam stability, container compatibility, particulate control, and in-use handling.

FAQs

Is cefoxitin compatible with 5% dextrose?

Cefoxitin sodium can be diluted in 5% dextrose injection under product-specific labeling. Compatibility depends on concentration, container, storage condition, and administration period.[1,2]

Can cefoxitin and dextrose be sold as a ready-to-use infusion?

Yes. A ready-to-use product can be developed as a sterile premixed infusion, but the marketed concentration, container, shelf life, and storage conditions require product-specific regulatory support.

Does dextrose create a new patent opportunity for cefoxitin?

Dextrose alone does not create meaningful exclusivity. Patent value would need to come from a technically distinctive formulation, stability profile, container, device, or manufacturing process.

Is cefoxitin subject to biosimilar competition?

No. Cefoxitin is a chemically synthesized small-molecule antibacterial, not a biologic. Competition proceeds through generic drug pathways rather than biosimilar approval.

What is the main barrier to launching a cefoxitin and dextrose product?

The principal barriers are sterile manufacturing, stability validation, container compatibility, market pricing, and dependable supply. Patent clearance for the basic combination is generally less difficult than achieving a commercially attractive shelf life.

References

1. U.S. Food and Drug Administration. (n.d.). Cefoxitin for injection, USP: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. Baxter Healthcare Corporation. (n.d.). Cefoxitin and dextrose injection: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Dextrose injection and sterile pharmaceutical requirements. USP.